PNC-27

Description

PNC-27 is an anti-cancer peptide that, in small in-vitro studies, has been shown to induce tumour cell necrosis. It is not currently approved for use in the United States (U.S.) and is currently being marketed online as a non-toxic potential cure for various cancers. Recently, the FDA issued warnings to the public regarding PNC-27 use, suggesting possible contamination and unknown side effects of the treatment. PNC-27 may be available in various dosage forms, such as a nebulized solution, intravenous solution, vaginal suppository, or rectal suppository. FDA has not evaluated or approved PNC-27 as safe and effective in treating any disease, including cancer[1].

Definition

PNC-27 is an anticancer peptide, containing an HDM-2-binding domain. PNC-27 shows anti-tumor activity and can be used in acute myeloid leukemia research.

in vitro

PNC-27 (50 μg/mL; 0-3 h) induces cancer cell death.
PNC-27 (50 μg/mL; 15 min) binds to cell membrane-bound HDM-2.

in vivo

PNC-27 (intraperitoneal injection; 40 mg/kg; once daily; 2-3 w) shows anti-leukemia activity in vivo.

References

[1] Aguon, P. M. et al. “Experimental PNC-27 Therapy and Massive GI Hemorrhage: A Complication or Coincidence?: 1879.” The American Journal of Gastroenterology 7 1 (2017): 0.

Raw materials

Preparation Products